EUVIMEDEUVIMED entdecken
Fallbericht

Atypical Dermatophytosis in Patients Treated by JAK Inhibitors

Jen A Barak Levitt, Nurit Kulish iD, Mira Hamed iD, Michael Ziv, Eran Cohen Barak

Experimental Dermatology · 2026-03 · 35 (3)

DOI: 10.1111/exd.70223 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Experimental Dermatology, online erschienen am 20.03.2026. Verfasst von Jen A Barak Levitt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Emek Medical Center, Afula, Israel. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Azetidines, Sulfonamides, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase (JAK) inhibitors are commonly used to treat immune‐mediated diseases by modulating the JAK–STAT signalling pathway. While these agents are therapeutically effective, they may also impair immunity, including antifungal response. Here, we present five cases of atypical dermatophyte infections in patients treated with baricitinib or upadacitinib. Their clinical presentations and treatment regimens were summarised to highlight the atypical features and the presumed effects of JAK inhibitors. Patients presented with erythematous indurated plaques, clustered firm papules, and widespread thin plaques with scaling and erosions. PCR and fungal cultures confirmed infections with Trichophyton tonsurans , Trichophyton rubrum , Trichophyton verrucosum , and Microsporum canis . Treatment with systemic antifungal agents such as terbinafine, itraconazole, and griseofulvin was effective. In some cases, the dosage of JAK inhibitors was reduced during antifungal therapy. Clinicians should be vigilant for cutaneous fungal infections in JAK inhibitor‐treated patients with new rashes. The immunomodulatory effect of JAK inhibitors may attenuate the clinical manifestation and lead to delayed recognition of dermatophytosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsAzetidinesSulfonamidesHeterocyclic Compounds, 3-RingTineaHumansPyrazolesAntifungal AgentsPurinesFemaleMaleMiddle AgedAdultTrichophytonMicrosporumAgedItraconazoleTerbinafineGriseofulvin

Stichwörter der Autor:innen

Janus kinase inhibitorsatypical dermatophytosisatypical fungal infectionsbaricitinibdermatophytosisupadacitinib

Substanzen

Janus Kinase InhibitorsPyrazolesAntifungal AgentsAzetidinesSulfonamidesPurinesbaricitinibHeterocyclic Compounds, 3-RingupadacitinibItraconazole

Autor:innen und Institutionen

  • Department of Dermatology, Emek Medical Center, Afula, Israel.
  • Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel.

ORCID-Profile: Nurit Kulish, Mira Hamed

Zitieren

APA

Barak Levitt, J. A., Kulish, N., Hamed, M., Ziv, M., & Barak, E. C. (2026). Atypical Dermatophytosis in Patients Treated by JAK Inhibitors. Experimental Dermatology, 35(3). https://doi.org/10.1111/exd.70223

Vancouver

Barak Levitt JA, Kulish N, Hamed M, Ziv M, Barak EC. Atypical Dermatophytosis in Patients Treated by JAK Inhibitors. Experimental Dermatology. 2026;35(3). doi:10.1111/exd.70223

BibTeX
@article{BarakLevitt2026,
  author = {Barak Levitt, Jen A and Kulish, Nurit and Hamed, Mira and Ziv, Michael and Barak, Eran Cohen},
  title = {Atypical Dermatophytosis in Patients Treated by JAK Inhibitors},
  journal = {Experimental Dermatology},
  year = {2026},
  volume = {35},
  number = {3},
  doi = {10.1111/exd.70223}
}
Kostenlos starten →